PROLINE ALAT (GPT) FS (IFCC mod.)
Alanine aminotransferase (ALAT/ALT), previously known as Glutamic Pyruvic Transaminase (GPT), is the most important enzyme in the aminotransferase or transaminase group, which catalyzes the conversion of α-keto acids to amino acids through the transfer of an amino group. As a liver-specific enzyme, ALAT will only increase significantly in hepatobiliary diseases. The AST/ALT ratio is crucial for differential diagnosis in liver diseases and is used to distinguish damage to the liver, heart, or skeletal muscles.
In liver cirrhosis, liver tissue is damaged and replaced by scar tissue (fibrosis), leading to portal hypertension. This high pressure forces blood to flow through alternative vessels, such as esophageal varices, which can rupture and cause bleeding. Additionally, alanine aminotransferase (ALAT) enzymes are released into the blood, indicating liver cell damage.
| ALAT levels in the body increase during: | ALAT levels in the body decrease during: |
| Hepatitis Virus | End-stage liver disease |
| Toxic Hepatitis | Renal hemodialysis and/or renal insufficiency |
| Mononucleosis Infection | |
| Cirrhosis | |
| Polymyositis | |
| Acute Pancreatitis |
The optimized UV test according to the IFCC (International Federation of Clinical Chemistry and Laboratory Medicine).
- Liquid reagent, open-system, ready to use without the need for reconstitution.
- Reagent functionality and installation testing guarantee.
- Good performance in linearity and stability.
- Available in MPK (multi-purpose kit) and dedicated kit types.
| Sample type | Serum atau Plasma |
| Measurement range | 3 U/L - 600 U/L |
| Analysis wavelength | 340 nm |
| Analysis mode | Kinetic |
| Reagent aspiration volume for manual instrument | R1: 1000 µL ; R2: 250 µL |
| Sample aspiration volume for manual instrument | 100 µL |
| Storage temperature | 2 – 8 °C |
| pH | R1: 6.85 |
| R2: 9,6 - 9,7 | |
| Odor characteristics | No distinctive odor |
| Visual characteristics | R1: Colorless, clear |
| R2: Slightly yellowish, clear | |
| On-board stability | With P-5-P: 6 days |
| Without P-5-P: 4 weeks | |
| Expiration date | 18 months |
| Catalogue Number | R1 Reagent Volume | R2 Reagent Volume |
| 1 2701 99 10 920 | 4 x 34 mL | 4x10 mL |
| 1 2701 99 10 921 | 4 x 21 mL | 4 x 6 mL |
| 1 2701 99 10 191 | 4 x 36 mL | 4 x 9 mL |
| 1 2701 99 10 022 | 5 x 20 mL | 1 x 25 mL |
| 1 2701 99 10 025 | 3 x 80 mL | 1 x 60 mL |
| 1 2701 99 10 029 | 3 x 200 mL | 1 x 150 mL |
| 1 2701 99 10 181 | 4 x 36 mL | 4 x 9 mL |
| 1 2701 99 10 965 | 6 x 25 mL | 6 x 6 mL |
| 1 2701 99 10 951 | 6 x 36 mL | 6 x 9 mL |
| 1 2701 99 10 914 | 6 x 60 mL | 6 x 15 mL |
| 1 2701 99 10 591 | 4 x 60 mL | 4 x 15 mL |
| 1 2701 99 10 027 | 2 x 100 mL | 2 x 25 mL |
| Reference Range: | ||
| Woman | <34 U/L | <0,57 μkat/L |
| Man | <45 U/L | <0,75 μkat/L |
| Child | <25 U/L - <30 U/L | <0,42 μkat/L - <0,50 μkat/L |
| Interfering Substances | Interference ≤ 10% up to (mg/dL) | Analytical Concentration (mg/dL) |
| Ascorbate | 30 | 121 |
| Conjugated Bilirubin | 50 | 49,8 |
| 55 | 93,8 | |
| Unconjugated Bilirubin | 45 | 46,1 |
| 45 | 85,7 | |
| Hemoglobin | 500 | 50,9 |
| 850 | 107 | |
| Lipemic (triglycerides) | 1000 | 35,5 |
| 1000 | 114 |
- Alanine Aminotransferase (ALAT/GPT) Reagent
- Doos
- Kit insert
- Reagents bottle
- Thomas L. Alanine aminotransferase (ALT), Aspartate aminotransferase (AST). In: Thomas L, editor. Clinical
Laboratory Diagnostics. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft; 1998. p. 55-65. - Moss DW, Henderson AR. Clinical enzymology. In: Burtis CA, Ashwood ER, editors. Tietz Textbook of
Clinical Chemistry. 3rd ed. Philadelphia: W.B Saunders Company; 1999. p. 617-721. - Bergmeyer HU, Horder M, Rej R. Approved Recommendation (1985) on IFCC Methods for the Measurement
of Catalytic Concentration of Enzymes. L Clin. Chem. Clin. Biochem 1986; 24: 481-495. - Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and
prevention. ClinChemLabMed 2007;45(9):1240-1243. - Guder WG, Zawta B et al. The Quality of Diagnostic Samples. 1st ed. Darmstadt: GIT Verlag; 2001; 14-5.
- Young DS. Effects of Drugs on Clinical Laboratory Tests. 5th ed. Volume 1 and 2. Washington, DC: The
American Association for Clinical Chemistry Press 2000.
- Liver disease
Contact our team to find out more product information and ordering
- Telp : +62 21 8984 2722
- WhatsApp : +62 815 1359 2626
- Email : marketing@proline.co.id
Contact our Technical support team for further assistance with product specifications, services and other technical documents.
- Telp : +62-21-8984-2722
- WhatsApp : +62-817-9324-884
- Email : technical.support@prodis.co.id